(Q37061969)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

David Valcarcel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

J Sierra

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

R Martino

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

B Sánchez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

S Brunet

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

21 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

425-437

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18209727%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705973

1 January 2020

exact match

0 references

cites work

Hematopoietic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Are matched unrelated donor transplants justified for AML in CR1?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Treatment of acute myeloblastic leukemia in adults. The GOELAM experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

FLT3 mutations: biology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Long-range multilocus haplotype phasing of the MHC

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Genomics of unrelated-donor hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Improving the outcome of unrelated donor stem cell transplantation by molecular matching

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

HLA mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the Internation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Adult umbilical cord blood transplantation: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Acute myeloid leukemia and myelodysplastic syndromes in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Can reduced-intensity allogeneic transplantation cure older adults with AML?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Marrow transplants from unrelated donors as treatment for acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Limits of HLA mismatching in unrelated hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leuk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705973

7 January 2021